{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:54:31Z","timestamp":1790056471855,"version":"4.0.1"},"reference-count":26,"publisher":"Bioscientifica","issue":"4","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a heterogeneous group of incurable cancers. Lenvatinib is an oral multiple kinase inhibitor that showed activity in grade 1\/2 GEP-NENs in the phase II TALENT trial, but a confirmatory phase III study has yet to be conducted. To investigate the real-world use of lenvatinib in treating patients with advanced GEP-NENs, we retrospectively analyzed a cohort of adults with unresectable neuroendocrine neoplasms (NENs) from two academic centers in Canada who received palliative treatment with lenvatinib. Progression-free survival (PFS), overall survival (OS) and the treating clinician assessment of best therapeutic response were analyzed in the entire cohort and in the subgroup of patients with GEP-NENs that would have been eligible for the TALENT trial. Overall, 33 patients, with mostly G1\/G2 (78.8%) metastatic NENs, received lenvatinib. The pancreas was the most common primary site (n = 16, 48.5%), followed by the small bowel (n = 12, 36.4%). The median number of prior lines of systemic therapy was 2 (range 1\u20135). The median initial, maximal and minimal doses (mg) were 12 (range 4\u201324), 12 (range 8\u201324) and 8 (range 4\u201324), respectively. The median PFS was 11.9 months (95% CI, 9.5\u2013NA), and the median OS was 17.5 months (95% CI, 12.7\u2013NA), with disease burden reduction seen in 21.9% (95% CI, 11.0\u201338.7) and 87.5% (95% CI, 71.9\u201395.3) of patients achieving disease control. The most frequent side effects reported were hypertension (60.6%), fatigue (39.4%), hypothyroidism (21.2%) and diarrhea (18.2%). This real-world cohort demonstrates encouraging evidence of lenvatinib activity in metastatic NENs, even when used at lower doses than previously studied in NENs.<\/jats:p>","DOI":"10.1530\/erc-24-0292","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:19:40Z","timestamp":1739186380000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":2,"title":["Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-7765","authenticated-orcid":true,"given":"Joao Paulo","family":"Solar Vasconcelos","sequence":"first","affiliation":[{"name":"BC Cancer Vancouver 1 , , ,","place":["Vancouver, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Eduardo","family":"Nunez Rodriguez","sequence":"additional","affiliation":[{"name":"Sunnybrook Hospital 2 , , ,","place":["Toronto, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6428-3401","authenticated-orcid":true,"given":"Ali","family":"Zaidi","sequence":"additional","affiliation":[{"name":"BC Cancer Vancouver 1 , , ,","place":["Vancouver, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharani","family":"Krishnan","sequence":"additional","affiliation":[{"name":"BC Cancer Vancouver 1 , , ,","place":["Vancouver, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helia","family":"Jafari","sequence":"additional","affiliation":[{"name":"BC Cancer Vancouver 1 , , ,","place":["Vancouver, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene","family":"Gill","sequence":"additional","affiliation":[{"name":"BC Cancer Vancouver 1 , , ,","place":["Vancouver, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Tan","sequence":"additional","affiliation":[{"name":"BC Cancer Abbotsford 3 , , ,","place":["Abbotsford, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Le","sequence":"additional","affiliation":[{"name":"BC Cancer Surrey 4 , , ,","place":["Surrey, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Chan","sequence":"additional","affiliation":[{"name":"BC Cancer Surrey 4 , , ,","place":["Surrey, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Yu","sequence":"additional","affiliation":[{"name":"BC Cancer Burnaby 5 , , ,","place":["Burnaby, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"McGhie","sequence":"additional","affiliation":[{"name":"BC Cancer Victoria Canada 6 , , ,","place":["Victoria, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Lim","sequence":"additional","affiliation":[{"name":"BC Cancer Vancouver 1 , , ,","place":["Vancouver, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"Sunnybrook Hospital 2 , , ,","place":["Toronto, Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-2132","authenticated-orcid":true,"given":"Jonathan M","family":"Loree","sequence":"additional","affiliation":[{"name":"BC Cancer Vancouver 1 , , ,","place":["Vancouver, British Columbia, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2026070905414107400_bib1","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070905414107400_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2026070905414107400_bib3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070905414107400_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026070905414107400_bib5","doi-asserted-by":"crossref","first-page":"R315","DOI":"10.1530\/ERC-17-0012","article-title":"Genetic and epigenetic drivers of neuroendocrine tumours (NET)","volume":"24","author":"Di Domenico","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2026070905414107400_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026070905414107400_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann Oncol"},{"key":"2026070905414107400_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000473892","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy \u2013 chemotherapy","volume":"105","author":"Garcia-Carbonero","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2026070905414107400_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"2026070905414107400_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/cncr.35145","article-title":"A call to action to advance patient-focused and decentralized clinical trials","volume":"130","author":"Harvey","year":"2024","journal-title":"Cancer"},{"key":"2026070905414107400_bib11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2026070905414107400_bib12","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070905414107400_bib13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026070905414107400_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000471880","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy \u2013 biotherapy and novel targeted agents","volume":"105","author":"Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2026070905414107400_bib15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070905414107400_bib16","article-title":"Therapy sequencing in patients with advanced neuroendocrine neoplasms","volume":"43","author":"Riechelmann","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026070905414107400_bib17","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1038\/s41467-021-24812-3","article-title":"The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets","volume":"12","author":"van Riet","year":"2021","journal-title":"Nat Commun"},{"key":"2026070905414107400_bib18","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"2026070905414107400_bib19","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026070905414107400_bib20","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070905414107400_bib21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905414107400_bib22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"2026070905414107400_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070905414107400_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"Ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"2026070905414107400_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070905414107400_bib26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/4\/ERC-24-0292.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/4\/ERC-24-0292.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0292\/144845\/erc-24-0292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0292\/144845\/erc-24-0292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:41:52Z","timestamp":1783590112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/4\/e240292\/25886\/Real-world-outcomes-of-lenvatinib-therapy-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0292","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"article-number":"e240292"}}